{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:13:07Z","timestamp":1794960787874,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T00:00:00Z","timestamp":1542758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T00:00:00Z","timestamp":1542758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 18987"],"award-info":[{"award-number":["IG 18987"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Critical regulation of bile acid (BA) pool size and composition occurs via an intensive molecular crosstalk between the liver and gut, orchestrated by the combined actions of the nuclear Farnesoid X receptor (FXR) and the enterokine fibroblast growth factor 19 (FGF19) with the final aim of reducing hepatic BA synthesis in a negative feedback fashion. Disruption of BA homeostasis with increased hepatic BA toxic levels leads to higher incidence of hepatocellular carcinoma (HCC). While native FGF19 has anti-cholestatic and anti-fibrotic activity in the liver, it retains peculiar pro-tumorigenic actions. Thus, novel analogues have been generated to avoid tumorigenic capacity and maintain BA metabolic action. Here, using BA related <jats:italic>Abcb4<\/jats:italic><jats:sup>\u2212\/\u2212<\/jats:sup> and <jats:italic>Fxr<\/jats:italic><jats:sup>\u2212\/\u2212<\/jats:sup> mouse models of spontaneous hepatic fibrosis and HCC, we explored the role of a novel engineered variant of FGF19 protein, called FGF19-M52, which fully retains BA regulatory activity but is devoid of the pro-tumoral activity. Expression of the BA synthesis rate-limiting enzyme <jats:italic>Cyp7a1<\/jats:italic> is reduced in FGF19-M52-treated mice compared to the GFP-treated control group with consequent reduction of BA pool and hepatic concentration. Treatment with the non-tumorigenic FGF19-M52 strongly protects <jats:italic>Abcb4<\/jats:italic><jats:sup>\u2212\/\u2212<\/jats:sup> and <jats:italic>Fxr<\/jats:italic><jats:sup>\u2212\/\u2212<\/jats:sup> mice from spontaneous hepatic fibrosis, cellular proliferation and HCC formation in terms of tumor number and size, with significant reduction of biochemical parameters of liver damage and reduced expression of several genes driving the proliferative and inflammatory hepatic scenario. Our data <jats:italic>bona fide<\/jats:italic> suggest the therapeutic potential of targeting the FXR-FGF19 axis to reduce hepatic BA synthesis in the control of BA-associated risk of fibrosis and hepatocarcinoma development.<\/jats:p>","DOI":"10.1038\/s41598-018-35496-z","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T16:26:27Z","timestamp":1542299187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4951-9543","authenticated-orcid":false,"given":"Raffaella Maria","family":"Gadaleta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Scialpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Peres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marica","family":"Cariello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Porru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Roda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Sabb\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Moschetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,21]]},"reference":[{"key":"35496_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","volume":"46","author":"J Ferlay","year":"2010","unstructured":"Ferlay, J., Parkin, D. M. & Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46, 765\u2013781 (2010).","journal-title":"Eur. J. Cancer"},{"key":"35496_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","volume":"2","author":"T Inagaki","year":"2005","unstructured":"Inagaki, T. et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2, 217\u2013225 (2005).","journal-title":"Cell Metab"},{"key":"35496_CR3","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","volume":"48","author":"I Kim","year":"2007","unstructured":"Kim, I. et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res. 48, 2664\u20132672 (2007).","journal-title":"J. Lipid Res."},{"key":"35496_CR4","first-page":"635","volume":"72","author":"R Cameron","year":"1981","unstructured":"Cameron, R., Imaida, K. & Ito, N. Promotive effects of deoxycholic acid on hepatocarcinogenesis initiated by diethylnitrosamine in male rats. Gan 72, 635\u2013636 (1981).","journal-title":"Gan"},{"key":"35496_CR5","first-page":"M110","volume":"10","author":"T Chen","year":"2011","unstructured":"Chen, T. et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol. Cell Proteomics. 10, M110 (2011).","journal-title":"Mol. Cell Proteomics."},{"key":"35496_CR6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/hep.21287","volume":"44","author":"AS Knisely","year":"2006","unstructured":"Knisely, A. S. et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 44, 478\u2013486 (2006).","journal-title":"Hepatology"},{"key":"35496_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40139-012-0003-6","volume":"1","author":"X Wang","year":"2013","unstructured":"Wang, X. et al. Bile Acid Receptors and Liver Cancer. Curr. Pathobiol. Rep. 1, 29\u201335 (2013).","journal-title":"Curr. Pathobiol. Rep."},{"key":"35496_CR8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","volume":"67","author":"F Yang","year":"2007","unstructured":"Yang, F. et al. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 67, 863\u2013867 (2007).","journal-title":"Cancer Res."},{"key":"35496_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/his.12312","volume":"64","author":"Y Zen","year":"2014","unstructured":"Zen, Y., Vara, R., Portmann, B. & Hadzic, N. Childhood hepatocellular carcinoma: a clinicopathological study of 12 cases with special reference to EpCAM. Histopathology 64, 671\u2013682 (2014).","journal-title":"Histopathology"},{"key":"35496_CR10","first-page":"1237","volume":"145","author":"TH Mauad","year":"1994","unstructured":"Mauad, T. H. et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am. J. Pathol. 145, 1237\u20131245 (1994).","journal-title":"Am. J. Pathol."},{"key":"35496_CR11","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/carcin\/bgl249","volume":"28","author":"I Kim","year":"2007","unstructured":"Kim, I. et al. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 28, 940\u2013946 (2007).","journal-title":"Carcinogenesis"},{"key":"35496_CR12","doi-asserted-by":"publisher","first-page":"41930","DOI":"10.1074\/jbc.M306309200","volume":"278","author":"T Kok","year":"2003","unstructured":"Kok, T. et al. Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein. J. Biol. Chem. 278, 41930\u201341937 (2003).","journal-title":"J. Biol. Chem."},{"key":"35496_CR13","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","volume":"284","author":"M Makishima","year":"1999","unstructured":"Makishima, M. et al. Identification of a nuclear receptor for bile acids. Science 284, 1362\u20131365 (1999).","journal-title":"Science"},{"key":"35496_CR14","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","volume":"284","author":"DJ Parks","year":"1999","unstructured":"Parks, D. J. et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 284, 1365\u20131368 (1999).","journal-title":"Science"},{"key":"35496_CR15","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","volume":"102","author":"CJ Sinal","year":"2000","unstructured":"Sinal, C. J. et al. Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis. Cell 102, 731\u2013744 (2000).","journal-title":"Cell"},{"key":"35496_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1053\/j.gastro.2004.04.009","volume":"127","author":"P Fickert","year":"2004","unstructured":"Fickert, P. et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 127, 261\u2013274 (2004).","journal-title":"Gastroenterology"},{"key":"35496_CR17","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1053\/gast.2000.20222","volume":"119","author":"JM De Vree","year":"2000","unstructured":"De Vree, J. M. et al. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 119, 1720\u20131730 (2000).","journal-title":"Gastroenterology"},{"key":"35496_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/hep.27274","volume":"61","author":"C Degirolamo","year":"2015","unstructured":"Degirolamo, C. et al. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Hepatology 61, 161\u2013170 (2015).","journal-title":"Hepatology"},{"key":"35496_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11549-7","volume":"7","author":"M Cariello","year":"2017","unstructured":"Cariello, M. et al. Long-term Administration of Nuclear Bile Acid Receptor FXR Agonist Prevents Spontaneous Hepatocarcinogenesis in Abcb4(\u2212\/\u2212) Mice. Sci. Rep. 7, 11203 (2017).","journal-title":"Sci. Rep."},{"key":"35496_CR20","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1101\/gad.1083503","volume":"17","author":"JA Holt","year":"2003","unstructured":"Holt, J. A. et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17, 1581\u20131591 (2003).","journal-title":"Genes Dev."},{"key":"35496_CR21","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1194\/jlr.M700351-JLR200","volume":"48","author":"D Jung","year":"2007","unstructured":"Jung, D. et al. FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. J. Lipid Res. 48, 2693\u20132700 (2007).","journal-title":"J. Lipid Res."},{"key":"35496_CR22","doi-asserted-by":"publisher","first-page":"e52711","DOI":"10.1371\/journal.pone.0052711","volume":"7","author":"MU Latasa","year":"2012","unstructured":"Latasa, M. U. et al. Regulation of amphiregulin gene expression by beta-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system. PLoS. One. 7, e52711 (2012).","journal-title":"PLoS. One."},{"key":"35496_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","volume":"19","author":"ET Sawey","year":"2011","unstructured":"Sawey, E. T. et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell 19, 347\u2013358 (2011).","journal-title":"Cancer Cell"},{"key":"35496_CR24","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/hep.22771","volume":"49","author":"FG Schaap","year":"2009","unstructured":"Schaap, F. G., van der Gaag, N. A., Gouma, D. J. & Jansen, P. L. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49, 1228\u20131235 (2009).","journal-title":"Hepatology"},{"key":"35496_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1053\/j.gastro.2011.10.028","volume":"142","author":"S Modica","year":"2012","unstructured":"Modica, S. et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 142, 355\u2013365 (2012).","journal-title":"Gastroenterology"},{"key":"35496_CR26","doi-asserted-by":"publisher","first-page":"e36713","DOI":"10.1371\/journal.pone.0036713","volume":"7","author":"DM French","year":"2012","unstructured":"French, D. M. et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS. One. 7, e36713 (2012).","journal-title":"PLoS. One."},{"key":"35496_CR27","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hep.28257","volume":"63","author":"M Zhou","year":"2016","unstructured":"Zhou, M. et al. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology 63, 914\u2013929 (2016).","journal-title":"Hepatology"},{"key":"35496_CR28","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","volume":"160","author":"K Nicholes","year":"2002","unstructured":"Nicholes, K. et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am. J. Pathol. 160, 2295\u20132307 (2002).","journal-title":"Am. J. Pathol."},{"key":"35496_CR29","doi-asserted-by":"publisher","first-page":"247ra100","DOI":"10.1126\/scitranslmed.3009098","volume":"6","author":"J Luo","year":"2014","unstructured":"Luo, J. et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci. Transl. Med. 6, 247ra100 (2014).","journal-title":"Sci. Transl. Med."},{"issue":"Suppl 1","key":"35496_CR30","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/S0168-8278(02)00429-4","volume":"38","author":"SL Friedman","year":"2003","unstructured":"Friedman, S. L. Liver fibrosis \u2014 from bench to bedside. J. Hepatol. 38(Suppl 1), S38\u2013S53 (2003).","journal-title":"J. Hepatol."},{"key":"35496_CR31","first-page":"3107","volume":"54","author":"N Nishida","year":"1994","unstructured":"Nishida, N. et al. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 54, 3107\u20133110 (1994).","journal-title":"Cancer Res."},{"key":"35496_CR32","first-page":"1019","volume":"12","author":"N Nishida","year":"1997","unstructured":"Nishida, N., Fukuda, Y., Ishizaki, K. & Nakao, K. Alteration of cell cycle-related genes in hepatocarcinogenesis. Histol. Histopathol. 12, 1019\u20131025 (1997).","journal-title":"Histol. Histopathol."},{"key":"35496_CR33","first-page":"5389","volume":"61","author":"NG Deane","year":"2001","unstructured":"Deane, N. G. et al. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res. 61, 5389\u20135395 (2001).","journal-title":"Cancer Res."},{"key":"35496_CR34","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.taap.2013.06.016","volume":"272","author":"G Li","year":"2013","unstructured":"Li, G. et al. Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice. Toxicol. Appl. Pharmacol. 272, 299\u2013305 (2013).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"35496_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.22342","volume":"48","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. et al. Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology 48, 289\u2013298 (2008).","journal-title":"Hepatology"},{"key":"35496_CR36","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/0008-5472.CAN-08-3357","volume":"69","author":"P Kaposi-Novak","year":"2009","unstructured":"Kaposi-Novak, P. et al. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res. 69, 2775\u20132782 (2009).","journal-title":"Cancer Res."},{"key":"35496_CR37","first-page":"657","volume":"21","author":"R Ohashi","year":"2001","unstructured":"Ohashi, R. et al. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res. 21, 657\u2013662 (2001).","journal-title":"Anticancer Res."},{"key":"35496_CR38","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/hep.25740","volume":"56","author":"B Kong","year":"2012","unstructured":"Kong, B. et al. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 56, 1034\u20131043 (2012).","journal-title":"Hepatology"},{"key":"35496_CR39","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1210\/me.2011-1383","volume":"26","author":"N Liu","year":"2012","unstructured":"Liu, N. et al. Hepatocarcinogenesis in FXR\u2212\/\u2212 mice mimics human HCC progression that operates through HNF1alpha regulation of FXR expression. Mol. Endocrinol. 26, 775\u2013785 (2012).","journal-title":"Mol. Endocrinol."},{"key":"35496_CR40","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1126\/science.1198363","volume":"331","author":"S Kir","year":"2011","unstructured":"Kir, S. et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331, 1621\u20131624 (2011).","journal-title":"Science"},{"key":"35496_CR41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/978-1-4614-0887-1_12","volume":"728","author":"BC Lin","year":"2012","unstructured":"Lin, B. C. & Desnoyers, L. R. FGF19 and cancer. Adv. Exp. Med. Biol. 728, 183\u2013194 (2012).","journal-title":"Adv. Exp. Med. Biol."},{"key":"35496_CR42","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/hep.22627","volume":"49","author":"KH Song","year":"2009","unstructured":"Song, K. H., Li, T., Owsley, E., Strom, S. & Chiang, J. Y. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 49, 297\u2013305 (2009).","journal-title":"Hepatology"},{"key":"35496_CR43","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/j.gastro.2015.07.029","volume":"149","author":"MA Avila","year":"2015","unstructured":"Avila, M. A. & Moschetta, A. The FXR-FGF19 Gut-Liver Axis as a Novel \u201cHepatostat\u201d. Gastroenterology 149, 537\u2013540 (2015).","journal-title":"Gastroenterology"},{"key":"35496_CR44","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.gastro.2015.05.043","volume":"149","author":"WE Naugler","year":"2015","unstructured":"Naugler, W. E. et al. Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized Livers. Gastroenterology 149, 728\u2013740 (2015).","journal-title":"Gastroenterology"},{"key":"35496_CR45","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","volume":"74","author":"M Zhou","year":"2014","unstructured":"Zhou, M. et al. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19. Cancer Res. 74, 3306\u20133316 (2014).","journal-title":"Cancer Res."},{"key":"35496_CR46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/sj.onc.1210623","volume":"27","author":"LR Desnoyers","year":"2008","unstructured":"Desnoyers, L. R. et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 27, 85\u201397 (2008).","journal-title":"Oncogene"},{"key":"35496_CR47","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/toxsci\/kfs011","volume":"126","author":"R Pai","year":"2012","unstructured":"Pai, R. et al. Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys. Toxicol. Sci. 126, 446\u2013456 (2012).","journal-title":"Toxicol. Sci."},{"key":"35496_CR48","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0378-4347(94)00544-F","volume":"665","author":"A Roda","year":"1995","unstructured":"Roda, A., Gioacchini, A. M., Cerre, C. & Baraldini, M. High-performance liquid chromatographic-electrospray mass spectrometric analysis of bile acids in biological fluids. J. Chromatogr. B Biomed. Appl. 665, 281\u2013294 (1995).","journal-title":"J. Chromatogr. B Biomed. Appl."},{"key":"35496_CR49","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"},{"key":"35496_CR50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/hep.510310136","volume":"31","author":"EM Brunt","year":"2000","unstructured":"Brunt, E. M. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 31, 241\u2013246 (2000).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35496-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35496-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35496-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T12:04:03Z","timestamp":1671624243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-35496-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,21]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["35496"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-35496-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,21]]},"assertion":[{"value":"20 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Brian Ko and Jian Luo are employers of NGM Biopharmaceuticals, San Francisco CA and provided the AAV with FGF19-M52 analogue and GFP controls. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"17210"}}